Review of the role and potential clinical value of m6A methylation modifications in the biological process of osteosarcoma

被引：0
作者：
Zhou, Huaqiang [1 ]
Shu, Rongbing [1 ]
Wu, Jianming [1 ]
Zhou, Jiangjun [2 ]
Yu, Zhuanyi [1 ]
Cheng, Qiuxin [1 ]
Peng, Zhihao [1 ]
Zhao, Min [1 ]
机构：
[1] Yingtan Peoples Hosp, Dept orthopaed Surg, Yingtan, Peoples R China
[2] 908Th Hosp Joint Logist Support Force PLA, Dept Orthoped, Nanchang, Peoples R China
来源：
FRONTIERS IN GENETICS | 2025年 / 16卷
关键词：
m6A modification; osteosarcoma; RNA methylation; epigenetics; writer; eraser; reader; MESSENGER-RNA METHYLATION; NUCLEAR-RNA; M(6)A METHYLTRANSFERASE; PROMOTES; SUBUNIT; N6-METHYLADENOSINE; PROLIFERATION; TRANSLATION; RECOGNITION; APOPTOSIS;
D O I：
10.3389/fgene.2025.1522622
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Osteosarcoma (OS), an aggressive bone tumor, is a substantial threat to the quality of life and survival of affected individuals. Despite recent improvements in OS therapies, the considerable variability and chemotherapy resistance of this cancer necessitate continuous research to discover new treatment targets and biomarkers. Recent epigenetic advances highlight the crucial role of N6-methyladenosine (m6A) methylation in cancer. In OS, m6A methylation has been demonstrated to be a pivotal component in the pathogenesis. This review introduces new findings regarding the association between m6A methylation regulators and OS, and summarizes the potential clinical applications of OS and m6A methylation regulators, including the role of m6A methylation in OS proliferation, growth, apoptosis, and cell migration, invasion, and metastasis; relationship between m6A methylation and OS chemotherapy resistance; and relationship between m6A methylation and OS prognosis. Our review had certain limitations. The interaction between m6A methylation regulators and other oncogenic factors, such as lncRNAs and ncRNAs, is not fully understood. We hope that these potential methods will be translated into clinical applications and effective treatment.
引用
收藏
页数：12
相关论文
共 101 条
[1]   HNRNPA2B1 Is a Mediator of m6A-Dependent Nuclear RNA Processing Events [J].
Alarcon, Claudio R. ;
Goodarzi, Hani ;
Lee, Hyeseung ;
Liu, Xuhang ;
Tavazoie, Saeed ;
Tavazoie, Sohail F. .
CELL, 2015, 162 (06) :1299-1308
[2]   ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression [J].
An, Xueying ;
Wu, Wenshu ;
Yang, Lin ;
Dong, Jian ;
Liu, Bin ;
Guo, Junxia ;
Chen, Jianmei ;
Guo, Baosheng ;
Cao, Wangsen ;
Jiang, Qing .
TRANSLATIONAL RESEARCH, 2023, 259 :62-71
[3]  
Beird HC, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572-022-00409-y
[4]  
Bokar JA, 1997, RNA, V3, P1233
[5]  
BOKAR JA, 1994, J BIOL CHEM, V269, P17697
[6]   Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human mRNA:m6 a methyltransferase [J].
Bujnicki, JM ;
Feder, M ;
Radlinska, M ;
Blumenthal, RM .
JOURNAL OF MOLECULAR EVOLUTION, 2002, 55 (04) :431-444
[7]   ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators [J].
Cai, Zhonglin ;
Xu, Huan ;
Bai, Gang ;
Hu, Hanjing ;
Wang, Di ;
Li, Hongjun ;
Wang, Zhong .
FRONTIERS IN ONCOLOGY, 2022, 12
[8]   MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway [J].
Cao, Dong ;
Ge, Shanshan ;
Li, Mengchun .
JOURNAL OF BONE ONCOLOGY, 2022, 33
[9]   YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis [J].
Chang, Guoqiang ;
Shi, Lei ;
Ye, Youqiong ;
Shi, Hailing ;
Zeng, Lixian ;
Tiwary, Shweta ;
Huse, Jason T. ;
Huo, Lei ;
Ma, Li ;
Ma, Yongjie ;
Zhang, Sicong ;
Zhu, Jianwei ;
Xie, Victoria ;
Li, Peng ;
Han, Leng ;
He, Chuan ;
Huang, Suyun .
CANCER CELL, 2020, 38 (06) :857-+
[10]   Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy [J].
Chang, Mengyu ;
Hou, Zhiyao ;
Wang, Man ;
Li, Chunxia ;
Lin, Jun .
ADVANCED MATERIALS, 2021, 33 (04)
12345678910